Karen Koski

BTIG’s Karen Koski believes the proprietary technology platform of Fulgent Genetics Inc (NASDAQ: FLGT) “drives multiple sustainable competitive advantages, including a broad and flexible test menu and an attractive cost structure.” Koski initiated coverage of the company with a...

BTIG has downgraded OraSure Technologies, Inc. (NASDAQ: OSUR) to Neutral, as the brokerage looks for a better entry point into the shares. Shares have materially outperformed BTIG's comp group of profitable small-cap diagnostics companies (+34 percent year-to-date versus the group's -18 percent...

BTIG sees competing bids for Cepheid (NASDAQ: CPHD) unlikely following its deal to be acquired by Danaher Corporation (NYSE: DHR) for $53 a share in cash. "Though the purchase price is essentially in line with CPHD's 52-week high ($53.19), we think its implied multiple of ~6x EV/NTM Sales is fair...

BTIG maintains its Buy rating on Agilent Technologies Inc (NYSE: A,) saying that the company's transformation is in its early stages and any weakness in shares on "conservative" fourth-quarter guidance offers a buying opportunity. Agilent reported third-quarter adjusted EPS of $0.49, which was $0....

BTIG’s Karen Koski expressed concern regarding T2 Biosystems Inc (NASDAQ: TTOO), which reported another quarter of weak T2Dx placement, as well as cartridge manufacturing issues, extended timeline for the completion of the T2Bacteria trial and the mixed commentary at ASM. Koski downgraded the...

Shares of Cerus Corporation (NASDAQ: CERS) were trading up 4.2 percent Thursday as news of research that successfully inactivated the Zika virus in human blood circulated among traders. BTIG analysts Karen Koski, Dr. Sean Lavin and Andrea Alfonso reiterated their "buy" rating for...